Researchers from the Dutch pre-exposure prophylaxis (PrEP) demonstration study, AmPrEP, have found an unexpectedly high rate of hepatitis C virus (HCV) infection in participants tested for it at baseline. The HCV prevalence seen was more typical of that seen in HIV-positive gay men rather than the ...

Researchers recently published their findings on a combination therapy for use in patients with hepatitis C (HCV) genotype 4 in PLoS One. According to the Belgian researchers, sofosbuvir in combination with simeprevir with or without ribarivirn was found to be safe and effective. According to the ...

U.S. FDA grants priority review to AbbVie for its investigational regimen of glecaprevir/pibrentasvir (G/P) for the treatment of chronic hepatitis C in all major genotypes (GT1-6) – If approved, G/P will provide an eight week, once-daily, ribavirin-free cure* for HCV patients without cirrhosis across all major ...

The National Institute for Health and Care Excellence has now published final guidance endorsing Epclusa as an option for the treatment of adults with chronic hepatitis C genotype 1-6 infection on the NHS in England and Wales. Epclusa – a once-daily, fixed-dose combination of the nucleotide ...

Currently most effective directly-acting antiviral agent for hepatitis C (HCV) treatment has already arrived to Ukraine! Alliance for Public Health launches the third phase of HCV treatment program for key populations. This phase stipulates using a direct-acting antiviral agent, which is new for Ukraine – Harvoni ...

European Medicines Agency grants accelerated assessment, validates Marketing Authorization Application for AbbVie’s investigational regimen of glecaprevir/pibrentasvir (G/P) for the treatment of chronic hepatitis C in all major genotypes (GT1-6) – If approved, G/P may provide a shorter, eight week, once-daily, ribavirin-free treatment option for the majority ...

A group of researchers is investigating whether or not interferon-free therapy could reverse the cognitive declines that appear to accompany infection with the hepatitis C virus (HCV), with or HIV coinfection. Felix Kleefeld, of Berlin, Germany, and colleagues examined how eradicating HCV affected the cognition of ...

For the first time in the United States, a 31-year-old male with primary sclerosing cholangitis received a liver transplant from a deceased donor infected with hepatitis C virus (HCV). Primary sclerosis cholangitis slowly damages the bile ducts in the liver. After Lorenzo Swank learned his liver ...

From the first days of annexation of Crimea and launch of the military operation in the east of Ukraine, Alliance for Public Health (hereinafter – Alliance) defined that one of its priorities was support of HIV, tuberculosis, viral hepatitis prevention and treatment programs, as well ...

European Medicines Agency validates Gilead’s Marketing Authorization Application for investigational chronic hepatitis C therapy sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) SOF/VEL/VOX granted an accelerated assessment by the European Medicines Agency FOSTER CITY, Calif., Jan. 20, 2017– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Marketing Authorization Application (MAA) for ...

Targeting chronic hepatitis B infections affecting more than 240 million people worldwide GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today (January 17) that it has entered into a research collaboration agreement with Georgia State University Research Foundation (GSU) to advance the ...

On January 16 the Scottish Medicines Consortium (SMC) published advice accepting Zepatier for routine use in NHS Scotland. Elbasvir-grazoprevir (Zepatier) was accepted for the treatment of chronic hepatitis C. Elbasvir-grazoprevir is a combination of two medicines that inhibit the replication of the hepatitis C virus and ...

Eight weeks of treatment with AbbVie’s investigational, pan-genotypic, ribavirin-free regimen of glecaprevir/pibrentasvir (G/P) for chronic hepatitis C achieved high SVR rates in genotype 1 Japanese patients. – 99 percent (n=105/106) of genotype 1 (GT1) chronic HCV-infected Japanese patients without cirrhosis achieved SVR with 8 weeks of ...

Vemlidy® is the first new treatment for chronic hepatitis B infection to be approved in the European Union in nearly a decade Gilead Sciences, Inc. (Nasdaq: GILD) announced that the European Commission has granted marketing authorization for Vemlidy® (tenofovir alafenamide, TAF) 25 mg, a once-daily tablet ...

Patients with hepatitis C virus infection who received an antiviral drug around the time they underwent liver transplantation saw a high rate of sustained virologic response, according to a Northwestern Medicine phase II clinical trial. The finding suggests that the therapy might be an effective ...

ELPA presents the stark findings of the 2016 Hep-CORE Report Berlin, 20 December 2016 – Fifty-two per cent (52%) of surveyed European (25) and Mediterranean Basin (2) countries lack national strategies to address viral hepatitis B or C despite the WHO World Health Assembly resolution calling ...

This week Large drop in HIV diagnoses in London gay men Four sexual health clinics serving large numbers of gay men in London have reported that they diagnosed far fewer gay men with HIV during Hepatitis C virus often found in rectal fluid Our understanding of how ...

With hepatitis C (HCV) being curable with direct-acting antivirals in eight to 12 weeks or less, the question arises whether we can transplant HCV-positive organs to HCV-negative patients safely with treatment. In a large study of U.S. kidney transplant recipients, five-year graft and patient survival ...